Diagnosing Halogen Gas Exposure and Eosinophil-driven Diseases

SLU ID 15-005 | Diagnostic biomarkers of leukocyte-mediated disease and halogen gas exposure

Intellectual Property Status

Seeking

  • Patented

  • Know-how based

  • Licensee

  • Development partner

  • Commercial partner

  • Investment

  • University spin out

Background

Currently, there are no biomarkers for halogen gas exposure. Additionally, there are no biomarkers for some eosinophil-driven diseases. Using biomarkers to identify the presence of disease avoids invasive surgical procedures to extract samples for pathology microscopic evaluation.

Overview

Researchers at Saint Louis University have developed a method of using glutathione adducts of 2-halofatty aldehydes (FALD-GSH) as an indicator of halogen gas exposure and pro-inflammatory leukocyte mediated disease.

Benefits

The potential benefits of this technology include:

  • Minimizing the time required to diagnose halogen gas exposure and Eosinophil-driven diseases

  • Minimizing the complexity of diagnosing halogen gas exposure and Eosinophil-driven diseases

  • Minimizing the need for invasive diagnostic procedures

Applications

The potential applications of this technology include:

  • Diagnosing halogen gas exposure

  • Diagnosing Eosinophil-driven diseases

Opportunity

Saint Louis University is seeking a partner to further develop and commercialize this technology.